Adamantiades‐Behcet's disease: From the first known descriptions to the era of the biologic agents
Authors:
- 1 October 2024
- journal article
- editorial
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (10) , e15353
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysisRheumatology International, 2023
- Age-related immunosenescence in Behçet’s diseaseRheumatology International, 2022
- Mortality associated with Behçet’s disease in France assessed by multiple-cause-of-death analysisClinical Rheumatology, 2022
- Rituximab as an effective therapeutic option in refractory Neuro-Behcet syndromeJournal of Neuroimmunology, 2020
- Epidemiology, morbidity and mortality in Behçet’s disease: a cohort study using The Health Improvement Network (THIN)Rheumatology, 2020
- Hulusi Behcet-A Life of Passion and Endeavor in DermatologyJAMA Dermatology, 2018
- Ustekinumab for Behçet's diseaseJournal of Autoimmunity, 2017
- Evaluation of the Long-Term Efficacy and Safety of Infliximab Treatment for Uveitis in Behçet's DiseaseOphthalmology, 2014
- Adalimumab for the treatment of Behcet's disease: experience in 19 patientsRheumatology, 2012
- A Historical Review of Early Descriptions of Adamantiades-Behçet's DiseaseJournal of Investigative Dermatology, 2002